Skip to main content

Advertisement

SpringerLink
Log in

Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

The objective is to define the therapeutic role of antiplatelet agents in a triple-negative breast cancer (TNBC) population.

Methods

We performed retrospective analysis using the UTSW TNBC registry containing data from 222 Stage II–III TNBC patients treated between 1998 and 2016. Univariate analysis and multivariable logistic regression models were constructed to identify factors associated with disease-free survival (DFS), distant metastases rate (DMR), and overall survival outcomes. Antiplatelet drug use was determined by review of electronic medical records.

Results

A total of 65 patients used antiplatelet (AP) agents, and 157 patients did not use AP agents. Median follow-up for AP and non-AP groups was 41.3 and 40.9 months, respectively. There was an improvement in the AP group compared with the control group in 5-year DFS (80.4% at 5 years compared with 62.3% in the control group, p = 0.04) and 5-year DMR (8.8 vs. 31.9%, p = 0.007). In multivariate analysis, AP use was found to be significantly associated with improvements in DFS and DMR.

Conclusions

We illustrate that antiplatelet agent use improves DMR and DFS among a stage II and III TNBC population despite our short follow-up evaluation. Longer follow-up evaluation will be required to determine additional outcome advantage for antiplatelet agent use. Our findings support consideration of investigation of antiplatelet therapy as an adjunctive therapy for TNBC at high risk for disease recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA Cancer J Clin 66(1):7–30

    Article  PubMed  Google Scholar 

  2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434

    Article  PubMed  Google Scholar 

  3. Stockmans G, Deraedt K, Wildiers H, Moerman P, Paridaens R (2008) Triple-negative breast cancer. Curr Opin Oncol 20(6):614–620

    Article  PubMed  Google Scholar 

  4. Anders CK, Carey LA (2009) Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 9(Suppl 2):S73–S81

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8(3):235–244

    Article  PubMed  Google Scholar 

  6. Scully OJ, Bay BH, Yip G, Yu Y (2012) Breast cancer metastasis. Cancer Genomics Proteomics 9(5):311–320

    CAS  PubMed  Google Scholar 

  7. Trousseau A (1865) Phlegmasia alba dolens. In: Trosseau A (ed) Clinique médicinale de l’Hotel-Dieu de Paris, vol 3, pp 645–712

  8. Lip GY, Chin BS, Blann AD (2002) Cancer and the prothrombotic state. Lancet Oncol 3(1):27–34

    Article  CAS  PubMed  Google Scholar 

  9. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846–1850

    Article  CAS  PubMed  Google Scholar 

  10. Lima LG, Monteiro RQ (2013) Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep 33(5):e00064

    Article  PubMed  PubMed Central  Google Scholar 

  11. Degen JL, Palumbo JS (2012) Hemostatic factors, innate immunity and malignancy. Thromb Res 129(Suppl 1):S1–S5

    Article  CAS  PubMed  Google Scholar 

  12. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH (2012) The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 119(4):924–932

    Article  PubMed  Google Scholar 

  13. Nash GF, Walsh DC, Kakkar AK (2001) The role of the coagulation system in tumour angiogenesis. Lancet Oncol 2(10):608–613

    Article  CAS  PubMed  Google Scholar 

  14. Falanga A, Marchetti M, Vignoli A (2013) Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 11(2):223–233

    Article  CAS  PubMed  Google Scholar 

  15. Thun MJ, Jacobs EJ, Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9(5):259–267

    Article  CAS  PubMed  Google Scholar 

  16. Wu KK (2000) Aspirin and salicylate: an old remedy with a new twist. Circulation 102(17):2022–2023

    Article  CAS  PubMed  Google Scholar 

  17. Gay LJ (2011) BF-H: contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123–134

    Article  CAS  PubMed  Google Scholar 

  18. Ready A, Velicer CM, McTiernan A, White E (2008) NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 109(3):533–543

    Article  CAS  PubMed  Google Scholar 

  19. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99(8):608–615

    Article  CAS  PubMed  Google Scholar 

  20. Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN (2007) Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 166(10):1150–1158

    Article  PubMed  Google Scholar 

  21. Gierach GL, Lacey JV Jr, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, Brinton LA (2008) Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 10(2):R38

    Article  PubMed  PubMed Central  Google Scholar 

  22. Friis S, Thomassen L, Sorensen HT, Tjonneland A, Overvad K, Cronin-Fenton DP, Vogel U, McLaughlin JK, Blot WJ, Olsen JH (2008) Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 17(2):88–96

    Article  PubMed  Google Scholar 

  23. Francis JL, Amirkhosravi A (2002) Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 28(1):29–38

    Article  CAS  PubMed  Google Scholar 

  24. Choe KS, Liauw SL (2013) Effects of aspirin on cancer initiation and progression. Expert Rev Anticancer Ther 13(2):115–117

    Article  CAS  PubMed  Google Scholar 

  25. Bosetti C, Gallus S, La Vecchia C (2009) Aspirin and cancer risk: a summary review to 2007. Recent Results Cancer Res 181:231–251

    Article  CAS  PubMed  Google Scholar 

  26. Hejna M, Raderer M, Zielinski CC (1999) Inhibition of metastases by anticoagulants. J Natl Cancer Inst 91(1):22–36

    Article  CAS  PubMed  Google Scholar 

  27. Akl EA, Kamath G, Kim SY, Yosuico V, Barba M, Terrenato I, Sperati F, Schunemann HJ (2007) Oral anticoagulation may prolong survival of a subgroup of patients with cancer: a Cochrane systematic review. J Exp Clin Cancer Res 26(2):175–184

    CAS  PubMed  Google Scholar 

  28. Smorenburg SM, Vink R, Otten HM, Swaneveld F, Buller HR (2001) The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 86(6):1586–1587

    CAS  PubMed  Google Scholar 

  29. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, Edwards RL, Headley E, Kim SH, O’Donnell JF et al (1984) Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53(10):2046–2052

    Article  CAS  PubMed  Google Scholar 

  30. Jacobs CDCS, Yan J et al (2014) Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. Cancer Biol Ther 15(6):699–706

    Article  PubMed  PubMed Central  Google Scholar 

  31. Choe KSCJ, Chan JM, Carroll PR, D’Amico AV, Liauw SL (2012) Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 30(28):3540–3544

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Elwood PCGA, Duthie GG, Mur LA, Morgan G (2009) Aspirin, salicylates, and cancer. Lancet 373(9671):1301–1309

    Article  CAS  PubMed  Google Scholar 

  33. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28(9):1467–1472

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Kwan ML, Habel LA, Slattery ML, Caan B (2007) NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 18(6):613–620

    Article  PubMed  PubMed Central  Google Scholar 

  35. Blair CK, Sweeney C, Anderson KE, Folsom AR (2007) NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 101(2):191–197

    Article  CAS  PubMed  Google Scholar 

  36. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294(1):47–55

    Article  CAS  PubMed  Google Scholar 

  37. Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84(9):1188–1192

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Takkouche B, Regueira-Mendez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100(20):1439–1447

    Article  CAS  PubMed  Google Scholar 

  39. Agrawal A, Fentiman IS (2008) NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 62(3):444–449

    Article  CAS  PubMed  Google Scholar 

  40. Gerotziafas GTPC, Hatmi M, Samama MM, Elalamy I (2008) Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb 36(3–4):204–211

    PubMed  Google Scholar 

  41. Rothwell PMFF, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759):31–41

    Article  CAS  PubMed  Google Scholar 

  42. Sotiriou CLM, Lagneaux L, Berchem G, Body JJ (1999) The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and -11. Anticancer Res 19(4B):2997–3006

    CAS  PubMed  Google Scholar 

  43. Natarajan KMN, Artemov D, Aboagye EO, Chacko VP, Bhujwalla ZM (2000) Phospholipid profiles of invasive human breast cancer cells are altered towards a less invasive phospholipid profile by the anti-inflammatory agent indomethacin. Adv Enzyme Regul 40:271–284

    Article  CAS  PubMed  Google Scholar 

  44. Could aspirin treat breast cancer? (2015). http://www.dana-farber.org/Newsroom/News-Releases/could-aspirin-treat-breast-cancer.aspx

  45. Pedersen AKFG (1984) Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311(19):1206–1211

    Article  CAS  PubMed  Google Scholar 

  46. Patrignani PPC (2016) Aspirin and cancer. J Am Coll Cardiol 68(9):967–976

    Article  CAS  PubMed  Google Scholar 

  47. Labelle MBS, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5):576–590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Guillem-Llobat PDM, Bruno A et al (2016) Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget 7(22):32462–32477

    PubMed  PubMed Central  Google Scholar 

  49. Lin NCE, Sohl J et al (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113(10):2638–2645

    Article  PubMed  PubMed Central  Google Scholar 

  50. Venkitaraman RJT, Dhadda A, Chaturvedi A, Upadhyay S (2009) Prognosis of patients with triple-negative breast cancer and brain metastasis. Clin Oncol (R Coll Radiol) 21(9):729–730

    Article  CAS  Google Scholar 

  51. Hines SLVL, Tan WW, McNeil RB, Perez EA, Jain A (2008) Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol 19(9):1561–1565

    Article  CAS  PubMed  Google Scholar 

  52. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, Ro J (2008) Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 10(1):R20

    Article  PubMed  PubMed Central  Google Scholar 

  53. Cancer Research UK. http://www.addaspirintrial.org/

  54. Liao XLP, Nishihara R et al (2012) Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367(17):1596–1606

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Department of Radiation Oncology, University of Texas Southwestern Medical Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA

      J. Shiao, K. M. Thomas, A. S. Rahimi, A. Spangler & D. W. Nathan Kim

    2. Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA

      R. Rao, M. DaSilva, M. Leitch, R. Wooldridge, A. Rivers & D. Farr

    3. Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA

      Jingsheng Yan & Xian-Jin Xie

    4. Department of Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA

      B. Haley

    Authors
    1. J. Shiao
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. K. M. Thomas
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. A. S. Rahimi
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. R. Rao
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Jingsheng Yan
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Xian-Jin Xie
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. M. DaSilva
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. A. Spangler
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. M. Leitch
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. R. Wooldridge
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. A. Rivers
      View author publications

      You can also search for this author in PubMed Google Scholar

    12. D. Farr
      View author publications

      You can also search for this author in PubMed Google Scholar

    13. B. Haley
      View author publications

      You can also search for this author in PubMed Google Scholar

    14. D. W. Nathan Kim
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to D. W. Nathan Kim.

    Ethics declarations

    Conflict of interest

    The authors declare that they have no conflict of interest.

    Additional information

    J. Shiao and K. M. Thomas have contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Shiao, J., Thomas, K.M., Rahimi, A.S. et al. Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients. Breast Cancer Res Treat 161, 463–471 (2017). https://doi.org/10.1007/s10549-016-4081-8

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s10549-016-4081-8

    Keywords

    Search

    Navigation